FOXP3 and cervical cancer: Neoadjuvant chemotherapy has been shown to improve the immune microenvironment of cervical cancer by reducing the number of Foxp3+ T cells, thereby mitigating immunosuppressive effects and enhancing antitumor immune responses (41).